An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market

By Steven Lavezoli, Regional Vice President, Business Development, Scorpius BioManufacturing

With the demand for biologic drugs growing steadily, biotech and biopharma developers are relying on outsourcing partners to meet their research, development, and production needs. A CDMO that offers end-to-end services, including process and analytical development, manufacturing, and regulatory support, can help developers meet timelines and gain a competitive advantage.

The biologics market is experiencing strong growth, with monoclonal antibodies being the most dominant type of biologic drug. To increase efficiency and productivity, the industry is adopting strategies such as process optimization, automation, and the use of single-use technologies. Digital transformation is also playing a significant role, with companies leveraging technologies like AI and machine learning to improve drug discovery and development.

However, the industry faces challenges such as workforce shortages, supply chain issues, and potential over-capacity. The COVID-19 pandemic has highlighted the need for flexibility and agility in the biopharmaceutical supply chain, leading to increased outsourcing and regionalization in manufacturing strategies.

Discover how a reputable and experienced CDMO offering a purpose-built facility with flexible capacity and state-of-the-art equipment can help biopharmaceutical companies bring their products to market quickly and efficiently.